Bristol Myers Squibb licenses cell therapy candidate from Obsidian

By The Science Advisory Board staff writers

September 15, 2020 -- Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology.

Obsidian's platform allows for the development of controllable cell and gene therapies. The technology provides a way to control protein degradation, permitting precise control of the timing and level of protein expression. The cell therapy for which Bristol Myers Squibb is gaining the license provides controlled expression of the immunomodulatory factor CD40L for the development of cell therapies in solid tumors and other malignancies.

This is the first opt-in decision made by Bristol Myers Squibb since the companies announced their collaboration to develop novel cell therapies in January 2019.

Under the agreement, Obsidian is eligible to receive potential future milestone and royalty payments.

Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.
Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple...
AACR launches $36M genomics project with big pharma
The American Association for Cancer Research (AACR) is launching a $36 million research project in collaboration with big pharma to expand its Genomics...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter